Melatonin ameliorates hepatic fibrosis via the melatonin receptor 2-mediated upregulation of BMAL1 and anti-oxidative enzymes
European Journal of Pharmacology · 2024
DOI: 10.1016/j.ejphar.2024.176337 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2024. Verfasst von Jea Il Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology, Republic of Korea. Hauptthemen laut MEDLINE: Melatonin. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Education.
Abstract (Originalsprache)
Hepatic fibrosis, when left untreated, causes serious health problems that progress to cirrhosis and, in some cases, liver cancer. Activation of hepatic stellate cells may be a key characteristic in the development of hepatic fibrosis. Melatonin, a pineal hormone, exerts anti-fibrotic effects; however, the exact mechanisms remain unclear. In this study, the beneficial effects of melatonin against hepatic fibrosis and the underlying mechanisms were investigated using the human hepatic stellate cell line, LX-2, and in vivo murine animal models. The results showed that melatonin suppressed the expression of transforming growth factor (TGF)-β1-induced fibrosis markers and production of reactive oxygen species in LX-2 cells. Either 4-phenyl-2-propionamidotetralin, a melatonin receptor 2 selective antagonist, or melatonin receptor 2 small interfering RNA abolished the suppressive effects of melatonin, suggesting the involvement of melatonin receptor 2 in melatonin-induced anti-fibrotic and anti-oxidative actions. Melatonin increased the expression of the brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1 (BMAL1), a positive circadian clock gene. BMAL1 knockdown reduced the anti-fibrotic and anti-oxidative effects of melatonin, demonstrating the protective effects of melatonin against TGF-β1-induced hepatic stellate cell activation by exhibiting melatonin receptor 2-BMAL1-anti-oxidative effects. In high-fat diet-induced and carbon tetrachloride-induced hepatic fibrosis models, oral melatonin administration decreased the expression of hepatic fibrosis markers and increased the expression of messenger RNA and levels of proteins of BMAL1 and melatonin receptor 2. Thus, melatonin exerted protective effects against hepatic fibrosis through melatonin receptor 2 activation, followed by an upregulation of the BMAL1-anti-oxidative enzyme pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology, Republic of Korea.
- Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology, Republic of Korea; Department of Pharmacology, College of Medicine, Gachon University, Incheon, 21999, Republic…
Förderung
- National Research Foundation of Korea
- Ministry of Education
Zitieren
APA
Kim, J. I., & Cheon, H. G. (2024). Melatonin ameliorates hepatic fibrosis via the melatonin receptor 2-mediated upregulation of BMAL1 and anti-oxidative enzymes. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2024.176337
Vancouver
Kim JI, Cheon HG. Melatonin ameliorates hepatic fibrosis via the melatonin receptor 2-mediated upregulation of BMAL1 and anti-oxidative enzymes. European Journal of Pharmacology. 2024. doi:10.1016/j.ejphar.2024.176337
BibTeX
@article{Kim2024,
author = {Kim, Jea Il and Cheon, Hyae Gyeong},
title = {Melatonin ameliorates hepatic fibrosis via the melatonin receptor 2-mediated upregulation of BMAL1 and anti-oxidative enzymes},
journal = {European Journal of Pharmacology},
year = {2024},
doi = {10.1016/j.ejphar.2024.176337}
}
EUVIMED